Elevations in liver enzymes showed a trend toward normalization after dose adjustment or discontinuation. 25 The safety profile of nintedanib in patients with autoimmune disease–related ILD was noted to be similar to that of patients without autoimmune disease–related ILD, 105 not significantly different in those patients who were taking concomitant glucocorticoids or DMARDs. 111 In patients taking with pirfenidone, gastrointestinal and skin-related events were the most commonly reported adverse events, but like nintedanib these were typically mild to moderate in severity.
← all excerpts
The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.
1
—
—